<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ADAPALENEÂ - adapaleneÂ gelÂ </strong><br>Sandoz Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<br>These highlights do not include all the information needed to use adapalene gel safely and effectively. See full prescribing information for adapalene gel, 0.3%.<br><br>Adapalene Gel, 0.3% For topical use only<br>Initial U.S. Approval: 1996</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"> Adapalene Gel, 0.3%, is a retinoid, indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in patients 12 years of age and older.  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"> Apply a thin film of adapalene gel, 0.3% to the entire face and any other affected areas of the skin once daily in the evening, after washing gently with a non-medicated soap.  (<a href="#section-2">2</a>)</p>
<p class="Highlighta"> For topical use only. Not for ophthalmic, oral or intravaginal use.  (<a href="#section-2">2</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta"> Each gram of adapalene gel, 0.3% contains 3 mg adapalene in an off-white aqueous gel.  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"> Adapalene gel, 0.3% should not be administered to individuals who are hypersensitive to adapalene or any of the components in the gel vehicle.  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><p class="Highlighta"> Ultraviolet Light and Environmental Exposure: Avoid exposure to sunlight and sunlamps. Wear sunscreen when sun exposure cannot be avoided <a href="#bef94f5a-731b-4de0-bce8-2f7d1fb335bc">(5.1)</a>. <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>, scaling, dryness, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>/burning were reported with use ofÂ  adapalene gel <a href="#b22cb6d1-539d-4940-a430-e25f5b53dd1f">(5.2)</a>. </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> The most frequently reported (â‰¥1%) adverse reactions were <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, skin <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, and sunburn. (<a href="#bbf78b0f-3a82-4dc3-915c-008b04c8c35c">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or <span class="Bold Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta"> As adapalene gel has the potential to induce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices, or lime) should be approached with caution. Use with caution, especially when using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.  (<a href="#section-7">7</a>)</p></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1Â  INDICATIONS &amp; USAGE 
</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2Â  DOSAGE &amp; ADMINISTRATION 
</span></a></h1>
<h1><a href="#section-3" class="toc"><span class="Bold">3Â  DOSAGE FORMS &amp; STRENGTHS 
</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4Â  CONTRAINDICATIONS 
</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5Â  WARNINGS AND PRECAUTIONS 
</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1Â Â  Ultraviolet Light and Environmental Exposure
</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2Â Â  Local Cutaneous Reactions
</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3Â Â  Allergic/ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6Â  ADVERSE REACTIONS 
</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1Â Â  Clinical Trials Experience
</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2Â Â  PostMarketing Experience
</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7Â  DRUG INTERACTIONS 
</span></a></h1>
<h1><a href="#section-8" class="toc"><span class="Bold">8Â  USE IN SPECIFIC POPULATIONS 
</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1Â  PREGNANCY
</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.3Â  NURSING MOTHERS 
</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.4Â  PEDIATRIC USE 
</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.5Â  GERIATRIC USE 
</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10Â  OVERDOSAGE 
</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11Â  DESCRIPTION 
</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12Â  CLINICAL PHARMACOLOGY 
</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1Â  MECHANISM OF ACTION 
</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2Â  PHARMACODYNAMICS 
</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3Â  PHARMACOKINETICS 
</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13Â  NONCLINICAL TOXICOLOGY 
</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1Â  CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY 
</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14Â  CLINICAL STUDIES 
</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16Â  HOW SUPPLIED/STORAGE AND HANDLING 
</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17Â  INFORMATION FOR PATIENTS 
</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1><span class="Bold">1Â  INDICATIONS &amp; USAGE 
</span></h1>
<p class="First"></p>
<p>Adapalene Gel, 0.3% is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in patients 12 years of age and older. <br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1><span class="Bold">2Â  DOSAGE &amp; ADMINISTRATION 
</span></h1>
<p class="First"></p>
<p></p>
<p>Apply a thin film of adapalene gel, 0.3% to the entire face and any other affected areas of the skin once daily in the evening, after washing gently with a non-medicated soap.Â  Avoid application to the areas of skin around eyes, lips, and mucous membranes.Â  A mild transitory <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">sensation of warmth</span> or slight <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> may occur shortly after the application of adapalene gel, 0.3%.Â  Patients should be instructed to minimize sun exposure.Â  Patients may be instructed to use moisturizers for relief of <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> or irritation.</p>
<p>If therapeutic results are not noticed after 12 weeks of treatment, therapy should be re-evaluated.</p>
<p>For topical use only.Â  Not for ophthalmic, oral or intravaginal use.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1><span class="Bold">3Â  DOSAGE FORMS &amp; STRENGTHS 
</span></h1>
<p class="First"></p>
<p>Each gram of adapalene gel, 0.3% contains 3 mg adapalene in an off-white aqueous gel.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1><span class="Bold">4Â  CONTRAINDICATIONS 
</span></h1>
<p class="First"></p>
<p>Adapalene gel, 0.3% should not be administered to individuals who are hypersensitive to adapalene or any of the components in the gel vehicle.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1><span class="Bold">5Â  WARNINGS AND PRECAUTIONS 
</span></h1>
<p class="First"></p>
<div class="Section">
<a name="bef94f5a-731b-4de0-bce8-2f7d1fb335bc"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1Â Â  Ultraviolet Light and Environmental Exposure
</span></h2>
<p class="First">Exposure to sunlight, including sunlamps, should be minimized during use of adapalene gel, 0.3%. Patients who normally experience high levels of sun exposure, and those with inherent sensitivity to sun, should be warned to exercise caution. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. Weather extremes, such as <span class="product-label-link" type="condition" conceptid="4221803" conceptname="Flatus">wind</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, also may be irritating to patients under treatment with adapalene gel, 0.3%.</p>
</div>
<div class="Section">
<a name="b22cb6d1-539d-4940-a430-e25f5b53dd1f"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2Â Â  Local Cutaneous Reactions
</span></h2>
<p class="First">Certain cutaneous signs and symptoms of treatment such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, dryness, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>/burning were reported with use of adapalene gel, 0.3%. These were most likely to occur during the first four weeks of treatment, were mostly mild to moderate in intensity, and usually lessened with continued use of the medication.Â  Depending upon the severity of these side effects, patients should be instructed to either use a moisturizer, reduce the frequency of application of adapalene gel, 0.3% or discontinue use.</p>
<p>Avoid contact with the eyes, lips, angles of the nose, and mucous membranes. The product should not be applied to cuts, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span>, eczematous or sunburned skin.Â  As with other retinoids, use of â€œwaxingâ€? as a depilatory method should be avoided on skin treated with adapalene.</p>
<p>As adapalene gel has the potential to induce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect and products with high concentrations of alcohol, astringents, spices, or lime) should be approached with caution.</p>
</div>
<div class="Section">
<a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3Â Â  Allergic/ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</span></h2>
<p class="First">Reactions characterized by symptoms such as <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, and <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">lip swelling</span>, requiring medical treatment have been reported during postmarketing use of adapalene. A patient should stop using adapalene gel, 0.3% and consult a doctor if experiencing allergic or anaphylactoid/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>) during treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1><span class="Bold">6Â  ADVERSE REACTIONS 
</span></h1>
<p class="First"></p>
<div class="Section">
<a name="bbf78b0f-3a82-4dc3-915c-008b04c8c35c"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1Â Â  Clinical Trials Experience
</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>In the multi-center, controlled clinical trial, signs and symptoms of local cutaneous irritation were monitored in 258 <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients who used adapalene gel, 0.3% once daily for 12 weeks. Of the patients who experienced cutaneous irritation (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, dryness, and/or burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>), the majority of cases were mild to moderate in severity, occurred early in treatment and decreased thereafter.Â  The incidence of local cutaneous irritation with adapalene gel, 0.3% from the controlled clinical study is provided in the following table:</p>
<p>Table 1: Physician assessed local cutaneous irritation with adapalene gel</p>
<table frame="void" width="624"><tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="top">
<span class="Bold">Incidence of Local Cutaneous Irritation with Adapalene Gel, 0.3% from Controlled Clinical Study</span><span class="Bold"><br></span><span class="Bold"> (N = 253*) </span><span class="Bold"><br></span><span class="Bold">Maximum Severity Scores Higher Than Baseline</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Mild </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Moderate </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Severe </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">66 (26.1%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">33 (13.0%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1 (0.4%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Scaling </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">110 (43.5%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">47 (18.6%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3 (1.2%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Dryness </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">113 (44.7%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">43 (17.0%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2 (0.8%) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Stinging</span> </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">72 (28.5%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">36 (14.2%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">9 (3.6%) </td>
</tr>
</tbody></table>
<p>* Total number of subjects with local cutaneous data for at least one post-Baseline evaluation.</p>
<p>Table 2: Patient reported local cutaneous adverse reactions with adapalene gel</p>
<table frame="void" width="612"><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Adapalene Gel, 0.3%</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Vehicle Gel</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">N=258</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">N=134</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Related* Adverse Reactions<br>Â Â Â  <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry Skin</span> <br>Â Â Â  Skin <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">Discomfort</span><br>Â Â Â  <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">Desquamation</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">57 (22.1%)<br>36 (14%)<br>15 (5.8%)<br> 4 (1.6%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6 (4.5%) <br>2 (1.5%)<br>0 (0.0%)<br> 0 (0.0%)</td>
</tr>
</tbody></table>
<p>* Selected adverse reactions defined by investigator as Possibly, Probably or Definitely Related</p>
<p>Related adverse reactions from the controlled clinical trial that occurred in greater than 1% of patients who used adapalene gel, 0.3% once daily included: <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> (14.0%), skin <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (5.8%), <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (1.9%), <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span> (1.6%), and sunburn (1.2%).Â  The following selected adverse reactions occurred in less than 1% of patients: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> flare, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>.</p>
<p>In a one-year, open-label safety study of 551 patients with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> who received adapalene gel, 0.3%, the pattern of adverse reactions was similar to the 12-week controlled study.</p>
</div>
<div class="Section">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2Â Â  PostMarketing Experience
</span></h2>
<p class="First">The following adverse reactions have been identified during post approval use of adapalene: <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, <span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">application site pain</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">lip swelling</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1><span class="Bold">7Â  DRUG INTERACTIONS 
</span></h1>
<p class="First"></p>
<p><span class="Bold">7.1 Concomitant Topical Medications</span></p>
<p>As adapalene gel, 0.3% has the potential to induce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices, or lime) should be approached with caution.Â  Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel, 0.3%. If these preparations have been used, it is advisable not to start therapy with adapalene gel, 0.3%, until the effects of such preparations have subsided.</p>
<p>No formal drug-drug interaction studies were conducted with adapalene gel, 0.3%.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1><span class="Bold">8Â  USE IN SPECIFIC POPULATIONS 
</span></h1>
<div class="Section">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold">8.1Â  PREGNANCY
</span></h2>
<p class="First"><span class="Bold">Teratogenic effects. Pregnancy Category C.</span></p>
<p>Retinoids may cause fetal harm, when administered to pregnant women.Â  Adapalene has been shown to be teratogenic in rats and rabbits when administered orally (see Animal Data below).Â  There are no adequate and well-controlled studies in pregnant women.Â  Adapalene gel, 0.3% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Â  The safety and efficacy of adapalene gel, 0.3% in pregnancy has not been established.</p>
<p><span class="Underline">Human Data </span></p>
<p>In clinical trials involving adapalene gel, 0.3% in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>, women of child-bearing potential initiated treatment only after having had a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> and used effective birth control measures during therapy.Â  However, 6 women treated with adapalene gel, 0.3% became pregnant.Â  One patient elected to terminate the pregnancy, two patients delivered healthy babies by normal delivery, two patients delivered prematurely and the babies remained in intensive care until reaching a healthy state and one patient was lost to follow-up.</p>
<p><span class="Underline">Animal Data </span></p>
<ul class="Disc">
<li>No teratogenic effects were seen in rats at oral doses of 0.15 to 5.0 mg/kg/day adapalene representing up to 6 times the maximum recommended human dose (MRHD) based on mg/mÂ² comparisons. Adapalene has been shown to be teratogenic in rats and rabbits when administered orally at doses â‰¥ 25 mg/kg representing 32 and 65 times, respectively, the MRHD based on mg/mÂ² comparisons. Findings included <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, <span class="product-label-link" type="condition" conceptid="432419" conceptname="Encephalocele">encephalocele</span> and skeletal abnormalities in the rat and <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernia</span>, <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">exophthalmos</span> and kidney and skeletal abnormalities in the rabbit.</li>
<li>Cutaneous teratology studies in rats and rabbits at doses of 0.6, 2.0, and 6.0 mg/kg/day exhibited no fetotoxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits.Â  Systemic exposure (AUC<span class="Sub">0-24h</span>) to adapalene 0.3% gel at topical doses of 6.0 mg/kg/day in rats and rabbits represented 5.7 and 28.7 times, respectively, the exposure in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with adapalene 0.3% gel applied to the face, chest and back (2 grams applied to 1000 cm<span class="Sup">2</span> of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> involved skin).</li>
</ul>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold">8.3Â  NURSING MOTHERS 
</span></h2>
<p class="First">It is not known whether adapalene is excreted in human milk.Â  Because many drugs are excreted in human milk, caution should be exercised when adapalene gel, 0.3% is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold">8.4Â  PEDIATRIC USE 
</span></h2>
<p class="First">Safety and effectiveness have not been established in pediatric patients below the age of 12.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2><span class="Bold">8.5Â  GERIATRIC USE 
</span></h2>
<p class="First">Clinical studies of adapalene gel, 0.3% did not include subjects 65 years of age and older to determine whether they respond differently than younger subjects.Â  Safety and effectiveness in geriatric patients age 65 and above have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">10Â  OVERDOSAGE 
</span></h1>
<p class="First">Adapalene gel, 0.3% is intended for topical use only. If the medication is applied excessively, no more rapid or better results will be obtained and marked <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, scaling, or skin <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> may occur.Â  Chronic ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of vitamin A.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1><span class="Bold">11Â  DESCRIPTION 
</span></h1>
<p class="First">Adapalene Gel, 0.3% contains adapalene 0.3% (3 mg/g) in a topical aqueous gel for use in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>, consisting of carbomer 980, edetate disodium, methylparaben, poloxamer 182, propylene glycol, purified water, and sodium hydroxide.Â  May contain hydrochloric acid for pH adjustment.</p>
<p>The chemical name of adapalene is 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid. It is a white to off-white powder, which is soluble in tetrahydrofuran, very slightly soluble in ethanol, and practically insoluble in water. The molecular formula is C<span class="Sub">28</span>H<span class="Sub">28</span>O<span class="Sub">3</span> and molecular weight is 412.53.Â  Adapalene is represented by the following structural formula.</p>
<div class="Figure"><img alt="14a84173-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cabba2c1-cf07-46aa-a2c3-1b815517b16b&amp;name=14a84173-figure-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1><span class="Bold">12Â  CLINICAL PHARMACOLOGY 
</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold">12.1Â  MECHANISM OF ACTION 
</span></h2>
<p class="First">Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein.Â  Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2><span class="Bold">12.2Â  PHARMACODYNAMICS 
</span></h2>
<p class="First">Clinical pharmacodynamic studies have not been conducted for adapalene gel, 0.3%.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2><span class="Bold">12.3Â  PHARMACOKINETICS 
</span></h2>
<p class="First">Systemic exposure of adapalene following topical application of adapalene gel was evaluated in a clinical study.Â  Sixteen <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients were treated once daily for 10 days with 2 grams of adapalene gel, 0.3% applied to the face, chest and back, corresponding to approximately 2 mg/cm<span class="Sup">2</span>. Fifteen patients had quantifiable (LOQ = 0.1 ng/mL) adapalene levels resulting in a mean C<span class="Sub">max</span> of 0.553 Â± 0.466 ng/mL on Day 10 of treatment.Â  The mean AUC<span class="Sub">0-24hr</span> was 8.37 Â± 8.46 ng.h/mL as determined in 15 of the 16 patients on Day 10.Â  The terminal apparent half-life, determined in 15 of 16 patients, ranged from 7 to 51 hours, with a mean of 17.2 Â± 10.2 hours.Â  Adapalene was rapidly cleared from plasma and was not detected 72 hours after the last application for all but one subject.Â  Exposure of potential circulating metabolites of adapalene was not measured.Â  Excretion of adapalene appears to be primarily by the biliary route.</p>
<p>In another clinical study in patients with moderate to moderately severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, adapalene gel, 0.3% or adapalene gel, 0.1% was applied to the face and optionally to the trunk, once daily for 12 weeks.Â  Seventy-eight (78) patients had plasma adapalene levels evaluated at Weeks 2, 8, and 12.Â  Of the 209 plasma samples analyzed, adapalene concentrations were below the limit of detection (LOD = 0.15 ng/mL) of the method in all samples but three.Â  For the three samples, traces of adapalene below the limit of quantification (LOQ = 0.25 ng/mL) of the method were found.Â  One of these samples was taken at Week 12 from a male patient treated with adapalene gel, 0.3% who treated the face and the trunk for eight weeks (thereafter, only the face was treated).Â  The second and third samples were from the Week 2 and 12 visits of a female patient treated with adapalene gel, 0.1% who treated only the face for 12 weeks.Â  In this study, the average daily usage of product was 1 g/day.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1><span class="Bold">13Â  NONCLINICAL TOXICOLOGY 
</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2><span class="Bold">13.1Â  CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY 
</span></h2>
<p class="First">Carcinogenicity studies with adapalene have been conducted in mice at topical doses of 0.4, 1.3, and 4.0 mg/kg/day, and in rats at oral doses of 0.15, 0.5, and 1.5 mg/kg/day.Â  These doses are up to 3 times (mice) and 2 times (rats) in terms of mg/mÂ²/day the potential exposure at the maximum recommended human dose (MRHD), assumed to be 2.5 grams adapalene gel, 0.3%. In the oral study, increased incidence of benign and malignant <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in the adrenal medullas of male rats was observed.</p>
<p>No photocarcinogenicity studies were conducted. Animal studies have shown an increased risk of skin neoplasms with the use of pharmacologically similar drugs (e.g., retinoids) when exposed to UV irradiation in the laboratory or to sunlight.Â  Although the significance of these studies to human use is not clear, patients should be advised to avoid or minimize exposure to either sunlight or artificial UV irradiation sources.</p>
<p>Adapalene did not exhibit mutagenic or genotoxic effects <span class="Italics">in vitro</span> (Ames test, Chinese hamster ovary cell assay, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> TK assay) and <span class="Italics">in vivo</span> (mouse micronucleus test).</p>
<p>Reproductive function and fertility studies were conducted in rats administered oral doses of adapalene in amounts up to 20 mg/kg/day (up to 26 times the MRHD based on mg/mÂ² comparisons).Â  No effects of adapalene were found on the reproductive performance or fertility of the F<span class="Sub">0</span> males or females.Â  There were also no detectable effects on the growth, development and subsequent reproductive function of the F<span class="Sub">1</span> offspring.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1><span class="Bold">14Â  CLINICAL STUDIES 
</span></h1>
<p class="First">The safety and efficacy of once daily use of adapalene gel, 0.3% for treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> were assessed in one 12 week, multi-center, controlled, clinical study, conducted in a total of 653 patients 12 to 52 years of age with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> of mild to moderate severity.Â  All female patients of child-bearing potential enrolled in the study were required to have a negative urine pregnancy test at the beginning of the study and were required to practice a highly effective method of contraception during the study. Female patients who were pregnant, nursing or planning to become pregnant were excluded from the study.</p>
<p>Patients enrolled in the study were Caucasian (72%), Hispanic (12%), African-American (10%), Asian (3%), and other (2%).Â  An equal number of males (49.5%) and females (50.5%) enrolled. Success was defined as â€œClearâ€? or â€œAlmost Clearâ€? in the Investigatorâ€™s Global Assessment (IGA).Â  The success rate, mean reduction, and percent reduction in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> lesion counts from Baseline after 12 weeks of treatment are presented in the following table:</p>
<p>Table 3: Clinical study primary efficacy results at Week 12</p>
<table frame="void" width="600"><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Adapalene</span><span class="Bold"><br></span><span class="Bold"> Gel, 0.3%</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Adapalene</span><span class="Bold"> Gel, 0.1%</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Vehicle Gel</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">N=258</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">N=261</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">N=134</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">IGA Success Rate </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">53 (21%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">41 (16%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12 (9%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Inflammatory Lesions<br> Mean Baseline Count<br> Mean Absolute (%) Reduction </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">27.7<br>14.4 (51.6%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">28.1 <br>13.9 (49.7%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">27.2 <br>11.2 (40.7%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Non-inflammatory Lesions<br> Mean Baseline Count<br> Mean Absolute (%) Reduction </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">39.4<br>16.3 (39.7%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">41.0<br>15.2 (35.2%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">40.0<br>10.3 (27.2%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Total Lesions<br> Mean Baseline Count<br> Mean Absolute (%) Reduction </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">67.1<br>30.6 (45.3%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">69.1<br>29.0 (41.8%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">67.2<br>21.4 (33.7%)</td>
</tr>
</tbody></table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1><span class="Bold">16Â  HOW SUPPLIED/STORAGE AND HANDLING 
</span></h1>
<p class="First">Adapalene Gel, 0.3% is supplied in the following size. <br>45 g tube â€“ NDC 0781-7142-19<br></p>
<p><span class="Bold Italics">Storage:</span> Store at 20Â° â€“ 25ÂºC (68Âº â€“ 77ÂºF); excursions permitted to 15Âº â€“ 30ÂºC (59Âº â€“ 86ÂºF) [see USP Controlled Room Temperature].Â  Protect from freezing.Â  Keep out of reach of children.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1><span class="Bold">17Â  INFORMATION FOR PATIENTS 
</span></h1>
<p class="First">â€œSee FDA-approved patient labeling (Patient Information)â€?</p>
<p><span class="Bold">Information for Patients</span></p>
<p>Patients using adapalene gel, 0.3%, should receive the following information and instructions:</p>
<ol class="Arabic">
<li>This medication is to be used only as directed by the physician.</li>
<li>Do not use more than the recommended amount and do not apply more than once daily as this will not produce faster results, but may increase irritation.</li>
<li>Apply a thin film of adapalene gel, 0.3% to the entire face and any other affected areas of the skin once daily in the evening, after washing gently with a non-medicated soap.</li>
<li>Avoid contact with the eyes, lips, angles of the nose, and mucous membranes.</li>
<li>Moisturizers may be used if necessary; however, products containing alpha hydroxy or glycolic acids should be avoided.</li>
<li>Exposure of the eye to this medication may result in reactions such as <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, and <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>.</li>
<li>This medication should not be applied to cuts, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span>, eczematous, or sunburned skin.</li>
<li>Wax depilation should not be performed on treated skin due to the potential for skin erosions.</li>
<li>Minimize exposure to sunlight including sunlamps.Â  Recommend the use of sunscreen products and protective apparel (e.g., hat) when exposure cannot be avoided.</li>
<li>During the early weeks of therapy, an apparent <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">exacerbation of acne</span> may occur.Â  This may be due to the action of the medication on previously unseen lesions and should not be considered a reason to discontinue therapy.</li>
<li>Contact the doctor if <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> occurs, as these may be signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</li>
<li>It is for external use only.</li>
</ol>
<p><br>Manufactured by<br>TOLMAR Inc.<br>Fort Collins, CO 80526 for<br>Sandoz Inc.<br>Princeton, NJ 08540</p>
<p>44457 Rev. 1 12/13</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1><span class="Bold">SPL PATIENT PACKAGE INSERT 
</span></h1>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">Important: </span>For use on the skin only (topical). Do not use Adapalene Gel, 0.3% in or on your mouth, eyes, or vagina.</p>
<p>Read this Patient Information that comes with Adapalene Gel, 0.3% before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your treatment or your medical condition. If you have any questions about Adapalene Gel, 0.3%, talk with your doctor or pharmacist.</p>
<p><span class="Bold">What is Adapalene Gel, 0.3%?</span></p>
<p>Adapalene Gel, 0.3% is a prescription medicine for skin use only (topical) used to treat <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in people 12 years of age and older.</p>
<p><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne vulgaris</span> is a condition in which the skin has blackheads, whiteheads and pimples.</p>
<p>It is not known if Adapalene Gel, 0.3% is safe and effective in children younger than 12 years of age or in people 65 years of age and older.</p>
<p><span class="Bold">Who should not use Adapalene Gel, 0.3%? </span></p>
<p><span class="Bold">Do not use Adapalene Gel, 0.3% if you:</span></p>
<p>â—?		are allergic to adapalene or any of the ingredients in Adapalene Gel, 0.3%. See the end of this Patient Information for a complete list of ingredients in Adapalene Gel.</p>
<p><span class="Bold">What should I tell my doctor before using Adapalene Gel, 0.3%?</span></p>
<p>Before you use Adapalene Gel, 0.3%, tell your doctor if you:</p>
<ul class="Disc">
<li>have other skin problems, including cuts or sunburn</li>
<li>have any other medical conditions</li>
<li>are pregnant or planning to become pregnant. It is not known if Adapalene Gel, 0.3% can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if Adapalene Gel, 0.3% passes into your breast milk and if it can harm your baby. Talk to your doctor about the best way to feed your baby if you use Adapalene Gel, 0.3%.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins and herbal supplements.</p>
<p>Especially tell your doctor if you use any other medicine for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. Using Adapalene Gel, 0.3% with topical medicines that contain sulfur, resorcinol or salicylic acid may cause <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I use Adapalene Gel, 0.3%?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Use Adapalene Gel, 0.3% exactly as your doctor tells you to use it. Adapalene Gel, 0.3% is for skin use only. Do not use Adapalene Gel, 0.3% in or on your mouth, eyes, or vagina.</dd>
<dt>â€¢</dt>
<dd>Apply Adapalene Gel, 0.3% 1 time a day. Do not use more Adapalene Gel, 0.3% than you need to cover the treatment area. Using too much Adapalene Gel, 0.3% or using it more than 1 time a day may increase your chance of <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>.</dd>
</dl>
<p><span class="Bold">Applying Adapalene Gel, 0.3%:</span></p>
<ul class="Disc">
<li>Wash the area where Adapalene Gel, 0.3% will be applied with a soap that does not contain a medicine and pat dry.</li>
<li>Adapalene Gel 0.3% comes in a tube, squeeze a small amount onto your fingertips and spread a thin layer over the entire face and any other affected areas.<br>
</li>
</ul>
<p><span class="Bold">What should I avoid while using Adapalene Gel, 0.3%?</span></p>
<dl>
<dt>â€¢</dt>
<dd>You should avoid spending time in sunlight or artificial sunlight, such as tanning beds or sunlamps. Adapalene Gel, 0.3% can make your skin sensitive to sun and the light from tanning beds and sunlamps. You should wear sunscreen and wear a hat and clothes that cover the areas treated with Adapalene Gel, 0.3% if you have to be in sunlight.</dd>
<dt>â€¢</dt>
<dd>You should avoid weather extremes such as <span class="product-label-link" type="condition" conceptid="4221803" conceptname="Flatus">wind</span> and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> as this may cause irritation to your skin.</dd>
<dt>â€¢</dt>
<dd>You should avoid applying Adapalene Gel, 0.3% to cuts, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span> and sunburned skin.</dd>
<dt>â€¢</dt>
<dd>You should avoid skin products that may dry or irritate your skin such as harsh soaps, astringents, cosmetics that have strong skin drying effects and products containing high levels of alcohol.</dd>
<dt>â€¢</dt>
<dd>You should avoid the use of â€œwaxingâ€? as a hair removal method on skin treated with Adapalene Gel, 0.3%.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of Adapalene Gel, 0.3%? </span></p>
<p><span class="Bold">Adapalene Gel, 0.3% may cause serious side effects including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</span> Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> are most likely to happen during the first 4 weeks of treatment and usually lessen with continued use of Adapalene Gel, 0.3%. Signs and symptoms of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> include:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Redness</span></li>
<li>Dryness</li>
<li>Scaling</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Stinging</span> or burning</li>
</ul>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span></span>. Adapalene Gel, 0.3% may cause an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> that may require medical treatment. Stop using Adapalene Gel, 0.3% and tell your doctor right away if you have any of these symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></li>
<li>trouble breathing or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyes, lips, tongue or throat</li>
</ul>
</dd>
</dl>
<p>You may use a moisturizer for relief of <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> or irritation, however you should avoid products that contain alpha hydroxy or glycolic acid.</p>
<p><span class="Bold">The most common side effects of Adapalene Gel, 0.3% are:</span></p>
<dl>
<dt>â€¢</dt>
<dd>skin <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">skin peeling</span></dd>
<dt>â€¢</dt>
<dd>sunburn</dd>
</dl>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of Adapalene Gel, 0.3%. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p>You may also report side effects to Sandoz Inc. at 1-800-525-8747.</p>
<p><span class="Bold">How should I store Adapalene Gel, 0.3%?</span></p>
<dl>
<dt>â€¢</dt>
<dd>StoreÂ  Adapalene Gel, 0.3% at room temperature between 68Â°F to 77Â°F (20Â° C to 25Â°C).</dd>
<dt>â€¢</dt>
<dd>Do not freeze Adapalene Gel, 0.3%.</dd>
</dl>
<p><span class="Bold">Keep Adapalene Gel, 0.3% and all medicines out of the reach of children. </span></p>
<p><span class="Bold">General information about Adapalene Gel, 0.3%</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use Adapalene Gel, 0.3% for a condition for which it was not prescribed. Do not give Adapalene Gel, 0.3% to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about Adapalene Gel, 0.3%. If you would like more information, talk with your doctor. You can also ask your doctor or pharmacist for information about Adapalene Gel, 0.3% that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in Adapalene Gel, 0.3%?</span></p>
<p>Active ingredient: adapalene</p>
<p>Inactive ingredients: carbomer 980, edetate disodium, methylparaben, poloxamer 182, propylene glycol, purified water and sodium hydroxide. May contain hydrochloric acid for pH adjustment.</p>
<p><span class="Bold">This Patient Information has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Manufactured by TOLMAR Inc.<br>Fort Collins, CO 80528 for<br>Sandoz Inc.<br>Princeton, NJ 08540<br>44457 Rev. 1 12/13</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<div class="Figure"><img alt="14a84173-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cabba2c1-cf07-46aa-a2c3-1b815517b16b&amp;name=14a84173-figure-02.jpg"></div>
<div class="Figure"><img alt="14a84173-figure-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cabba2c1-cf07-46aa-a2c3-1b815517b16b&amp;name=14a84173-figure-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADAPALENEÂ 		
					</strong><br><span class="contentTableReg">adapalene gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0781-7142</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ADAPALENE</strong> (ADAPALENE) </td>
<td class="formItem">ADAPALENE</td>
<td class="formItem">3Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE C</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLOXAMER 182</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-7142-19</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">45 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200298</td>
<td class="formItem">04/28/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Sandoz Inc.
							(110342024)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">TOLMAR Inc.</td>
<td class="formItem"></td>
<td class="formItem">791156578</td>
<td class="formItem">MANUFACTURE(0781-7142), ANALYSIS(0781-7142), PACK(0781-7142), LABEL(0781-7142), API MANUFACTURE(0781-7142), API/FDF ANALYTICAL TESTING(0781-7142)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>14a84173-d292-4b38-a48f-01756a77a01f</div>
<div>Set id: cabba2c1-cf07-46aa-a2c3-1b815517b16b</div>
<div>Version: 1</div>
<div>Effective Time: 20140428</div>
</div>
</div>Â <div class="DistributorName">Sandoz Inc.</div></p>
</body></html>
